GEN Exclusives

More »

GEN News Highlights

More »
Dec 9, 2009

Pfizer and Crown Team Up to Develop Treatments for Asian Cancers

  • Pfizer is partnering with oncology services company Crown Bioscience to develop novel therapeutics for cancers prevalent in Asia. The joint research will be carried out at Crown’s new facility near Shanghai and aims to discover and advance multiple candidates for clinical development.

    Crown will receive an upfront payment and research funding under the terms of the deal with Pfizer. It is also eligible to preclinical and development milestones as products progress.

    Based in California, Crown operates wholly owned research facilities at campuses in Beijing and Taicang, China, and in Indianapolis. The company claims its CrystalClear™ and HuPrime™ platforms provide unique capabilities in lead optimization and translational oncology for the development of clinical candidates.


Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »